A share price of LAVA Therapeutics NV [LVTX] is currently trading at $1.31, up 6.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LVTX shares have gain 21.30% over the last week, with a monthly amount drifted -0.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
LAVA Therapeutics NV [NASDAQ: LVTX] stock has seen the most recent analyst activity on December 12, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $2 from $11. Previously, JMP Securities downgraded its rating to Mkt Perform on December 11, 2024. On October 25, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $26 on April 19, 2021. JP Morgan initiated its recommendation with a Overweight and recommended $22 as its price target on April 19, 2021. Jefferies started tracking with a Buy rating for this stock on April 19, 2021, and assigned it a price target of $23.
LAVA Therapeutics NV experienced fluctuations in its stock price throughout the past year between $0.85 and $3.20. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. LAVA Therapeutics NV [NASDAQ: LVTX] shares were valued at $1.31 at the most recent close of the market. An investor can expect a potential return of 358.02% based on the average LVTX price forecast.
Analyzing the LVTX fundamentals
Trailing Twelve Months sales for LAVA Therapeutics NV [NASDAQ:LVTX] were 11.98M which represents 1313.60% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.48%, Pretax Profit Margin comes in at -2.04%, and Net Profit Margin reading is -2.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.65 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2367 points at the first support level, and at 1.1633 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3667, and for the 2nd resistance point, it is at 1.4233.
Ratios To Look Out For
To put it in perspective, the Current Ratio for LAVA Therapeutics NV [NASDAQ:LVTX] is 4.40. In addition, the Quick Ratio stands at 4.40 and the Cash Ratio stands at 1.94. Considering the valuation of this stock, the price to sales ratio is 2.88, the price to book ratio is 1.24.
